Thank you for donating!

You can donate using the following services.

Annual Family Conference

Our Annual Family Conference and Interactive Workshop on Niemann-Pick Diseases is the largest event in the NPUK calendar, bringing together affected individuals, families, health and research professionals under one roof.

This year we returned to Wyboston Lakes, Bedfordshire, over the weekend of 21st-23rd September 2018, to celebrate our 25th Conference! Wyboston Lakes is one of our favourite locations, with many memories made over the years, and we look forward to welcoming friends old and new, those newly diagnosed, living with Niemann-Pick or those that have experienced bereavement. This year’s Conference once again offered the opportunity to hear the latest developments regarding therapies and clinical trials for ASMD Niemann-Pick disease types A and B, and Niemann-Pick disease type C, plus related care issues, breakout sessions and workshops. You can view the programme in full, here.

The Interactive Workshop on Niemann-Pick Diseases, an event for professional delegates only, took place on Friday 21st September. Hosted by Professor Fran Platt, University of Oxford, the meeting will feature clinical and scientific presentations and workshops on relevant topics, including clinical management, research and potential therapies – you can view the Interactive Workshop programme, here.

If you would like further information on the Annual Family Conference & Interactive Workshop please contact NPUK directly by email at: info@npuk.org, or by phone on: 0191 415 0693. 

Latest news

11.06.19

Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)

Orphazyme plans to meet with the US Food and Drug Administration (FDA) to discuss the pathway forward during the Summer and will provide an update after it has received written comments from the FDA...

Read more

03.06.19

CTD Holdings Closes $7.4 Million Private Placement

CTD Holdings, Inc. (OTCQB: CTDH)("CTD" or the "Company"), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it closed its previously announced private placement of securities with a group of institutional and accredited investors that included directors and officers of the Company.

Read more
View all news Subscribe